Public Meeting on Patient-Focused Drug Development for Sarcopenia

["FDA Office of Women's Health" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Public Meeting on Patient-Focused Drug Development for Sarcopenia

Register Today.

March 2017

www.fda.gov/womens

Public Meeting on Patient-Focused Drug Development for Sarcopenia

�

On April 6, 2017, from 1:00 pm to 5:00 pm, FDA is conducting a public meeting on Patient-Focused Drug Development (PFDD) for Sarcopenia. FDA is interested in obtaining patient perspectives on the impact of sarcopenia on daily life and patient views on treatment approaches.�Registration to attend the meeting must be received by April 6, 2017.

In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on June 6, 2017.

Register for the meeting

Submit comments to the public docket

Please share this update with your network, members, constituents, and community.
FDA Office of Women's Health,�owh@xxxxxxx, 301�796�9440
10903 New Hampshire Avenue, WO32�Room 2333, Silver Spring, MD 20993

---

Subscriber Services:
Manage Preferences��|��Unsubscribe��|��Help with this service

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) � 10903 New Hampshire Ave � Silver Spring, MD 20993 � 1-888-INFO-FDA (1-888-463-6332)